The DOI matches its Crossref record; 189 of the 189 references it cites were found in a registry or an index.
The interleukin (IL)-1 cytokine family – Balance between agonists and antagonists in inflammatory diseases
Open accessAbstract
The interleukin (IL)-1 family of cytokines comprises 11 members, including 7 pro-inflammatory agonists (IL-1α, IL-1β, IL-18, IL-33, IL-36α, IL-36β, IL-36γ) and 4 defined or putative antagonists (IL-1R antagonist (IL-1Ra), IL-36Ra, IL-37, and IL-38) exerting anti-inflammatory activities. Except for IL-1Ra, IL-1 cytokines do not possess a leader sequence and are secreted via an unconventional pathway. In addition, IL-1β and IL-18 are produced as biologically inert pro-peptides that require cleavage by caspase-1 in their N-terminal region to generate active proteins. N-terminal processing is also required for full activity of IL-36 cytokines. The IL-1 receptor (IL-1R) family comprises 10 members and includes cytokine-specific receptors, co-receptors and inhibitory receptors. The signaling IL-1Rs share a common structure with three extracellular immunoglobulin (Ig) domains and an intracellular Toll-like/IL-1R (TIR) domain. IL-1 cytokines bind to their specific receptor, which leads to the recruitment of a co-receptor and intracellular signaling. IL-1 cytokines induce potent inflammatory responses and their activity is tightly controlled at the level of production, protein processing and maturation, receptor binding and post-receptor signaling by naturally occurring inhibitors. Some of these inhibitors are IL-1 family antagonists, while others are IL-1R family members acting as membrane-bound or soluble decoy receptors. An imbalance between agonist and antagonist levels can lead to exaggerated inflammatory responses. Several genetic modifications or mutations associated with dysregulated IL-1 activity and autoinflammatory disorders were identified in mouse models and in patients. These findings paved the road to the successful use of IL-1 inhibitors in diseases that were previously considered as untreatable.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The interleukin-1 family: back to the future
Garlanda, C., Dinarello, C. A., & Mantovani, A. (2013) · Immunity · doi:10.1016/j.immuni.2013.11.010 · Cited by 1,945
Agostini, L., Martinon, F., Burns, K., McDermott, M. F., Hawkins, P. N., & Tschopp, J. (2004) · Immunity · doi:10.1016/s1074-7613(04)00046-9 · Cited by 1,768
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases
Dinarello, C. A., Simon, A., & van der Meer, J. W. M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3800 · Cited by 1,768
Hoffman, H. M., Mueller, J. L., Broide, D. H., Wanderer, A. A., & Kolodner, R. D. (2001) · Nature Genetics · doi:10.1038/ng756 · Cited by 1,682
Interleukin-36–Receptor Antagonist Deficiency and Generalized Pustular Psoriasis
Marrakchi, S., Guigue, P., Renshaw, B. R., Puel, A., Pei, X.-Y., Fraitag, S., Zribi, J., Bal, E., Cluzeau, C., Chrabieh, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013068 · Cited by 998
An Autoinflammatory Disease with Deficiency of the Interleukin-1–Receptor Antagonist
Aksentijevich, I., Masters, S. L., Ferguson, P. J., Dancey, P., Frenkel, J., van Royen-Kerkhoff, A., Laxer, R., Tedgård, U., Cowen, E. W., Pham, T.-H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0807865 · Cited by 987
Interleukin-1 Type II Receptor: A Decoy Target for IL-1 That Is Regulated by IL-4
Colotta, F., Re, F., Muzio, M., Bertini, R., Polentarutti, N., Sironi, M., Giri, J. G., Dower, S. K., Sims, J. E., & Mantovani, A. (1993) · Science · doi:10.1126/science.8332913 · Cited by 980
Neonatal-Onset Multisystem Inflammatory Disease Responsive to Interleukin-1β Inhibition
Goldbach-Mansky, R., Dailey, N. J., Canna, S. W., Gelabert, A., Jones, J., Rubin, B. I., Kim, H. J., Brewer, C., Zalewski, C., Wiggs, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055137 · Cited by 930
IL-1 pathways in inflammation and human diseases
Gabay, C., Lamacchia, C., & Palmer, G. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.4 · Cited by 897
Self-citationUse of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
Lachmann, H. J., Kone-Paut, I., Kuemmerle-Deschner, J. B., Leslie, K. S., Hachulla, E., Quartier, P., Gitton, X., Widmer, A., Patel, N., & Hawkins, P. N. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810787 · Cited by 869
Cited by
Pro-inflammatory cytokines: The link between obesity and osteoarthritis
Wang, T., & He, C. (2018) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2018.10.002 · Cited by 1,034
Akdis, M., Aab, A., Altunbulakli, C., Azkur, K., Costa, R. A., Crameri, R., Duan, S., Eiwegger, T., Eljaszewicz, A., Ferstl, R., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.06.033 · Cited by 912
The IL-1 cytokine family and its role in inflammation and fibrosis in the lung
Borthwick, L. A. (2016) · Seminars in Immunopathology · doi:10.1007/s00281-016-0559-z · Cited by 294
Inflammasomes and Cancer: The Dynamic Role of the Inflammasome in Tumor Development
Kantono, M., & Guo, B. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01132 · Cited by 133
Zhao, N., Li, C.-C., Di, B., & Xu, L.-L. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102515 · Cited by 103
Metadata
- Authors
- Palomo, J., Dietrich, D., Martin, P., Palmer, G., & Gabay, C.
- Venue
- Cytokine
- Publisher
- Elsevier BV
- Published
- 2015-11
- Volume
- 76
- Issue
- 1
- Pages
- 25-37
- ISSN
- 1043-4666 (ISSN-L)
- OpenAlex
- W879479010
- Cited by
- 447
- References
- 189
- FWCI
- 17.50
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The interleukin (IL)-1 cytokine family – Balance between agonists and antagonists in inflammatory diseases. https://app.cochat.ai/papers/10.1016/j.cyto.2015.06.017
- The paper
- Palomo, J., Dietrich, D., Martin, P., Palmer, G., & Gabay, C. (2015). The interleukin (IL)-1 cytokine family – Balance between agonists and antagonists in inflammatory diseases. Cytokine. https://doi.org/10.1016/j.cyto.2015.06.017
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
